Understanding how specific proteins influence blood cell development
RUNX1-mediated regulation of MEP fate specification
This study looks at how a protein called RUNX1 helps decide whether certain blood cell precursors turn into platelets or red blood cells, and it aims to find new ways to help patients with acute myeloid leukemia (AML) by understanding these processes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11081717 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms that guide the development of blood cell progenitors, specifically focusing on how the RUNX1 protein affects the fate of megakaryocyte-erythroid progenitors (MEP). By examining how RUNX1 is modified by other proteins, the study aims to uncover how these changes influence whether these progenitors become platelets or red blood cells. Patients with acute myeloid leukemia (AML) may benefit from insights gained through this research, as it explores fundamental processes that could lead to new treatment strategies. The research employs advanced techniques in cell and molecular biology, along with proteomics, to analyze the behavior of these progenitor cells.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are individuals diagnosed with acute myeloid leukemia or related blood disorders.
Not a fit: Patients with non-hematological conditions or those not diagnosed with blood cell disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating acute myeloid leukemia and improving blood cell production.
How similar studies have performed: Previous research has shown promising results in understanding blood cell development, making this approach both relevant and potentially impactful.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Krause, Diane S — Yale University
- Study coordinator: Krause, Diane S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.